Welcome to our dedicated page for Teva Pharm news (Ticker: TEVA), a resource for investors and traders seeking the latest updates and insights on Teva Pharm stock.
Teva Pharmaceutical Industries Ltd. (TEVA) is a global leader in generic medicines and biosimilars, delivering cost-effective healthcare solutions across 60+ countries. This dedicated news hub provides investors and professionals with verified updates on Teva’s strategic initiatives, regulatory milestones, and market developments.
Find official press releases, earnings reports, and analysis covering Teva’s core operations in generics manufacturing, innovative therapies, and active pharmaceutical ingredients (APIs). Our curated feed includes updates on FDA approvals, partnership announcements, patent developments, and sustainability initiatives impacting the pharmaceutical sector.
Bookmark this page to monitor Teva’s progress in biosimilar innovation, supply chain expansions, and responses to industry trends. All content is sourced from verified channels to support data-driven decisions in the evolving healthcare landscape.
Teva Pharmaceuticals has announced results from a post hoc analysis of a 3-year open-label extension study for AUSTEDO (deutetrabenazine) tablets in treating tardive dyskinesia (TD). Published in The American Journal of Geriatric Psychiatry, this study evaluated efficacy and safety in patients under and over 55 years. TD affects approximately 500,000 individuals in the U.S., with higher rates in older patients. The analysis may guide treatment decisions, particularly for older adults, although the findings highlight the need for cautious interpretation due to the uncontrolled data.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) reported Q2 2021 revenues of $3,910 million, a slight increase of 1% year-over-year. Despite a 5% revenue decline in North America primarily from COPAXONE and Anda, overall profitability improved, reflected by GAAP net income of $207 million, or $0.19 per share. Free cash flow reached $625 million, and net debt reduced by $500 million to $22.7 billion. Teva lowered its revenue outlook for 2021 due to pandemic impacts but reaffirmed earnings and cash flow guidance. Notably, AUSTEDO sales rose, and AJOVY achieved $70 million in net sales worldwide.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced significant leadership changes aimed at enhancing its North America Commercial operations. Brendan O’Grady will depart the company, with Sven Dethlefs appointed as the new head of North America Commercial. Other changes include Mark Sabag transitioning to Executive Vice President, International Markets Commercial, Galia Inbar promoted to Chief Human Resources Officer, and Eli Shani elevated to Executive Vice President, Global Marketing and Portfolio. These changes are effective August 15, 2021.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will announce its financial results for Q2 2021 on July 28, 2021, at 7:00 a.m. ET. A conference call will follow at 8:00 a.m. ET, accessible via dial-in or live webcast. This event is part of Teva's ongoing commitment to transparency and stakeholder engagement. Teva has a diverse portfolio of over 3,500 products, serving around 200 million patients daily. The company remains focused on its generics and specialty medicines sector, though it faces forward-looking risks related to competition and regulatory issues.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has entered into a strategic partnership with Bioeq AG for the exclusive commercialization of FYB201, a biosimilar candidate for Lucentis® in Europe, Canada, Israel, and New Zealand. This collaboration leverages Teva's vast distribution network and Bioeq's biosimilar development capabilities. Teva will handle commercialization while Bioeq manages development and supply. Both companies will share revenue from this agreement, enhancing Teva's biosimilar portfolio and expanding patient access to affordable treatments for chronic diseases.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced that Japan's Ministry of Health approved AJOVY (fremanezumab) for preventive migraine treatment in adults. With an annual migraine prevalence of 8.4% in Japan, this long-acting injection offers flexible dosing options. AJOVY, developed in partnership with Otsuka Pharmaceutical, demonstrates statistical significance in clinical trials, achieving primary endpoints. Teva aims to enhance patient lives with this new treatment option.
Teva Pharmaceuticals has launched the first generic version of PERFOROMIST® (formoterol fumarate inhalation solution) in the U.S., targeting bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD). This product, approved by the FDA, addresses a market with annual sales of over $299 million. Teva leads in the generic market, boasting over 500 available products and more than 100 pending first-to-files. The launch signifies Teva's commitment to providing accessible medication while expanding its existing portfolio of generic medicines.
Teva Pharmaceuticals has launched a generic version of SOOLANTRA® (ivermectin) Cream, 1% in the U.S. for treating rosacea lesions. Teva is a leader in generic medicines with over 550 FDA-approved products. SOOLANTRA® generated annual sales exceeding $115 million in the U.S. Teva emphasizes that their ivermectin cream is not intended for oral, ophthalmic, or intravaginal use, highlighting potential risks during pregnancy and breastfeeding. The company remains focused on expanding its generics portfolio amid competitive market conditions.
Teva Pharmaceuticals announced new data on AJOVY (fremanezumab) at the American Headache Society meeting, highlighting clinical and real-world efficacy for treating migraines. The presentation includes a 12-month extension study from the HALO clinical program, addressing both episodic and chronic migraines. Key findings show that patients experienced statistically significant reductions in migraine days, with notable results among those with comorbid conditions like depression and anxiety. AJOVY remains the only long-acting anti-CGRP injection approved in the US.